Stevens Capital Management’s Meridian Bioscience Inc VIVO Stock Holding History

Stevens Capital Management’s Portfolio VIVO Stock Details VIVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-21,332	Closed	-$303K	–	1026
2018 Q1	$303K	Buy	+21,332	New	+$316K	0.01%	606
2017 Q4	–	Sell	-16,999	Closed	-$243K	–	1092
2017 Q3	$243K	Buy	+16,999	New	+$243K	0.01%	715
2016 Q3	–	Sell	-19,260	Closed	-$376K	–	1202
2016 Q2	$376K	Buy	+19,260	New	+$378K	0.02%	638
2013 Q3	–	Sell	-9,438	Closed	-$203K	–	1256
2013 Q2	$203K	Buy	+9,438	New	+$204K	0.01%	805

Other funds holding VIVO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SFM

Systematic Financial Management Teaneck, New Jersey $4.36B AUM 40.56% 1-Year Est. Return

Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Stevens Capital Management's VIVO Position: Q2 2018 in Review

Stevens Capital Management sold out of Meridian Bioscience Inc (VIVO) in Q2 2018, closing a stake of 21,332 shares — an estimated $303K sold.

Stevens Capital Management first reported a position in VIVO in Q2 2013 and held it in 4 quarters. The position peaked at $376K in Q2 2016. 177 funds tracked by Wall St. Rank hold VIVO as of Q2 2018.

Stevens Capital Management reported no remaining Meridian Bioscience Inc position as of Q2 2018 after selling out during the quarter.
Stevens Capital Management sold 21,332 Meridian Bioscience Inc shares in Q2 2018, an estimated $303K.
Stevens Capital Management first reported a position in Meridian Bioscience Inc in Q2 2013 and held it in 4 quarters.
Stevens Capital Management's Meridian Bioscience Inc position peaked at $376K in Q2 2016.
177 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q2 2018.

Based on Stevens Capital Management's 13F filing for Q2 2018, filed 9 Aug 2018.